Adult height in patients with familial male-limited precocious puberty and the role of an aromatase inhibitor in patient management.

Abstract

BACKGROUND:

There is little adult height data in patients with familial male-limited precocious puberty (FMPP) and no management consensus. We assessed the treatment and adult height in local patients with FMPP and those reported in the literature.

METHODS:

Growth data were obtained on four local patients with FMPP and a search performed to obtain management details and adult height data on cases in the literature. UK (90) population standards were used to calculate standard deviation scores (SDS).

RESULTS:

Adult height data were available on 25 men with FMPP of whom 21 were treated. Median adult height SDS of patients was -1.5 SD with a mid-parental target of -0.6 SD (p=0.1). Eight patients (32%) had an adult height above the mid-parental target and seven patients (28%) had a height >2 SD below the mean. The median height SD was -0.03 in untreated patients and +0.5 SD in those receiving an aromatase inhibitor. There was no relationship between height and age at presentation.

CONCLUSIONS:

Aromatase inhibitor therapy is associated with a positive height outcome in FMPP but the outcome with and without intervention is unpredictable. Clinicians need to be cautious when counselling families about the potential height outcome in FMPP.

• Authors: Laura C Lane, Josephine Flowers, Helen Johnstone, Tim Cheetham
• Journal: Journal of pediatric endocrinology & metabolism : JPEM (J Pediatr Endocrinol Metab) Vol. 31 Issue 5 Pg. 551-560 (Apr 25 2018) ISSN: 2191-0251 [Electronic] Germany
• PMID: 29654692 (Publication Type: Case Reports, Journal Article)

Chemical References

• Aromatase Inhibitors

Topics

• Adolescent
• Adult
• Aromatase Inhibitors (therapeutic use)
• Body Height (drug effects)
• Child
• Child, Preschool
• Disease Management
• Humans
• Male
• Prognosis
• Puberty, Precocious (drug therapy, physiopathology)